Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  NeuBase Therapeutics, Inc.    NBSE

NEUBASE THERAPEUTICS, INC.

(NBSE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
8.4(c) 8.62(c) 8.37(c) 8.2(c) 7.835(c) Last
128 084 57 620 148 999 65 053 156 733 Volume
-4.11% +2.62% -2.90% -2.03% -4.45% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -17,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -9,21x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -24,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,38x
Yield 2021 -
Capitalization 190 M 190 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 15
Free-Float 78,0%
More Financials
Company
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a... 
More about the company
Notations Surperformance© of NeuBase Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about NEUBASE THERAPEUTICS, INC.
10/27NEUBASE THERAPEUTICS : CEO, Dietrich A. Stephan, Ph.D., to Present Manufacturing..
AQ
10/26NEUBASE THERAPEUTICS' : CEO, Dietrich A. Stephan, Ph.D., to Present "Manufacturi..
PU
10/14NEUBASE THERAPEUTICS : Announces Addition of Peter Nielsen, Ph.D., Inventor of P..
AQ
10/13NEUBASE THERAPEUTICS : Announces Addition of Peter Nielsen, Ph.D., Inventor of P..
AQ
10/13NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D., Inventor of ..
GL
10/06NEUBASE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creatio..
AQ
09/29NEUBASE THERAPEUTICS : to Present at the Chardan Virtual 4th Annual Genetic Medi..
AQ
09/28NEUBASE THERAPEUTICS : to Present at the Chardan Virtual 4th Annual Genetic Medi..
AQ
09/28NeuBase Therapeutics to Present at the Chardan Virtual 4th Annual Genetic Med..
GL
09/18NEUBASE THERAPEUTICS : to Present at the Myotonic Dystrophy Foundation 2020 Virt..
AQ
09/17NEUBASE THERAPEUTICS : to Present at the Myotonic Dystrophy Foundation 2020 Virt..
AQ
09/17NeuBase Therapeutics to Present at the Myotonic Dystrophy Foundation 2020 Vir..
GL
09/11NEUBASE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
09/08NEUBASE THERAPEUTICS : to Present at Upcoming Investor Conferences in September ..
AQ
09/08NeuBase Therapeutics to Present at Upcoming Investor Conferences in September..
GL
More news
News in other languages on NEUBASE THERAPEUTICS, INC.

- No features available -

More news
Chart NEUBASE THERAPEUTICS, INC.
Duration : Period :
NeuBase Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUBASE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 15,67 $
Last Close Price 8,20 $
Spread / Highest target 120%
Spread / Average Target 91,1%
Spread / Lowest Target 58,5%
EPS Revisions
Managers
NameTitle
Dietrich A. Stephan President, Chief Executive Officer & Director
William R. Mann Chief Operating Officer
Samuel I. Backenroth Chief Financial Officer, Secretary & Treasurer
Robert Friedlander Consulting Chief Medical Officer
Danith Ly Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEUBASE THERAPEUTICS, INC.13.89%190
LONZA GROUP AG56.63%44 852
SEAGEN INC.68.34%33 467
CELLTRION, INC.33.15%29 849
IQVIA HOLDINGS INC.0.09%29 650
MODERNA, INC.264.42%28 126